EML4-ALK fusion gene

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9029521
SERIAL NO

13468730

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ASTELLAS PHARMA INC.;CUREGENE K.K.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Furutani, Takashi Tokyo, JP 35 243
Kuromitsu, Sadao Tokyo, JP 17 315
Mano, Hiroyuki Tokyo, JP 86 1015
Shindo, Nobuaki Tokyo, JP 22 230
Soga, Takatoshi Tokyo, JP 17 246

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 12, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00